MARKET

DSGN

DSGN

Design Therapeutics, Inc.
NASDAQ
9.82
+0.05
+0.51%
After Hours: 9.82 0 0.00% 16:10 12/04 EST
OPEN
9.68
PREV CLOSE
9.77
HIGH
10.02
LOW
9.33
VOLUME
320.15K
TURNOVER
--
52 WEEK HIGH
10.02
52 WEEK LOW
2.600
MARKET CAP
559.38M
P/E (TTM)
-8.2730
1D
5D
1M
3M
1Y
5Y
1D
Craig-Hallum bullish on Design Therapeutics, initiates with a Buy
TipRanks · 2d ago
Design Therapeutics Price Target Raised to $14.00/Share From $7.00 by Leerink Partners
Dow Jones · 2d ago
Design Therapeutics Raised to Outperform From Market Perform by Leerink Partners
Dow Jones · 2d ago
Leerink Partners Upgrades Design Therapeutics to Outperform, Raises Price Target to $14
Benzinga · 2d ago
Design Therapeutics initiated with a Buy at Craig-Hallum
TipRanks · 2d ago
Design Therapeutics upgraded to Outperform from Market Perform at Leerink
TipRanks · 2d ago
DESIGN THERAPEUTICS INC <DSGN.O>: LEERINK PARTNERS RAISES TO OUTPERFORM FROM MARKET PERFORM; RAISES TARGET PRICE TO $14 FROM $7
Reuters · 2d ago
Weekly Report: what happened at DSGN last week (1124-1128)?
Weekly Report · 4d ago
More
About DSGN
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.

Webull offers Design Therapeutics Inc stock information, including NASDAQ: DSGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DSGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DSGN stock methods without spending real money on the virtual paper trading platform.